Pharming Group N.V. (NASDAQ: PHAR) saw its stock price surge 12.78% in Thursday's pre-market trading session following the release of its first quarter 2025 financial results and an updated business outlook. The biopharmaceutical company, focused on developing innovative therapies for patients with rare diseases, reported significant growth and raised its full-year revenue guidance.

The company's Q1 2025 total revenues increased by 42% to $79.1 million compared to the same period last year, substantially beating analyst estimates of $67.73 million. This growth was primarily driven by RUCONEST, Pharming's treatment for hereditary angioedema (HAE), which saw a 49% revenue increase to $68.6 million. Additionally, Joenja, the company's therapy for activated phosphoinositide 3-kinase delta syndrome (APDS), contributed $10.5 million in revenue, up 9% from Q1 2024.

Encouraged by these strong results, Pharming raised its 2025 total revenue guidance to between $325 million and $340 million, representing a 9% to 14% year-over-year growth. The company also reported progress in its clinical pipeline, including advancements in regulatory approvals for Joenja in various markets and the continuation of pivotal trials for KL1333 in mitochondrial diseases. These developments, combined with the strong financial performance, have bolstered investor confidence in Pharming's growth prospects, leading to the significant stock price increase.